MedPharm announces it has successfully reconfirmed its cGMP and GLP certification in 2017
MedPharm, the world leader in formulation and development services for topical and transdermal pharmaceuticals, has announced that after recent successful MHRA inspections, it has renewed its cGMP and GLP accreditations.
This recent re-certification confirms the confidence that MedPharm’s clients, their clients’ investors and regulators have in the data supplied by MedPharm as part of regulatory submissions. This applies equally for new investigational products and performance testing data submitted to support product quality, shelf life and in the in vitro bioequivalence of new generic products.
”These successful inspections underline MedPharm’s focus on quality and compliance and its dedication to ensuring that customers projects are completed on time”, said MedPharm’s Chief Executive Officer, Dr Andrew Muddle. “Our accredited facilities and procedures allow MedPharm to support customers across the full range of services from pre-formulation to the manufacture of batches for the clinic using validated analytical and manufacturing methods. It gives our customers the confidence that any risks in their topical or transdermal development program will be minimized, increasing the probability of a successful outcome”.
Notes to editors
MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognised for their scientific rigour by regulators and investors. MedPharm has fully established R&D centres in the USA and UK and has its global HQ in Guildford, UK.